Ratings Surperformance

Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B

Ratings ESG MSCI

Ratings BioCryst Pharmaceuticals, Inc.: Strengths and Weaknesses

  • From a short-term investment perspective, the company presents a deteriorated fundamental situation
Highlights: BioCryst Pharmaceuticals, Inc.
  • Its low valuation, with P/E ratio at -4.16 and 14.37 for the ongoing fiscal year and 2027 respectively, makes the stock pretty attractive with regard to earnings multiples.
  • Growth remains a strong point in this company. In their sales forecast, analysts sound optimistic with regard to sales prospects.
  • Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
  • The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
  • Consensus analysts have strongly revised their opinion of the company over the past 12 months.
  • The group usually releases upbeat results with huge surprise rates.
Weaknesses: BioCryst Pharmaceuticals, Inc.
  • The company's currently anticipated earnings per share (EPS) growth for the next few years is a notable weakness.
  • The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
  • For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
  • For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
  • The overall consensus opinion of analysts has deteriorated sharply over the past four months.
  • The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.

Rating Financials

BioCryst Pharmaceuticals, Inc. SectorUnited States

Fundamentals

-

Growth

Revenue growth

EPS growth

FCF growth

Profitability

EBITDA Margin

EBIT Margin

Net Margin

Capital Efficiency

-

ROA

-

ROCE

-

ROE

-

Financial Health

-

Gearing

-

Leverage

-

Capital Intensity

Balance sheet growth

-

Long Term balance sheet growth

-

Long term revenue growth

Long term EPS growth

More ratings

Rating Valuation

BioCryst Pharmaceuticals, Inc. SectorUnited States

Global Valuation

-

Enterprise Value

-

EV/Revenue

-

EV/EBITDA

-

EV/FCF

-

Equity Valuation

-

P/E

PBR

-

Dividend Yield

-

EV/EBIT

-

CAPEX/Revenue

More ratings

Rating Consensus

BioCryst Pharmaceuticals, Inc. SectorUnited States

Consensus

Analysts' buy/sell recommendations

Analysts' recommendations evolution (1 year)

Analysts' recommendations evolution (4 months)

Analysts' target price

Analysts' target price evolution (1 year)

Analysts' target price evolution (4 months)

Analysts' recommendations evolution (7 days)

Target Price evolution (7 days)

More ratings

Rating Business Predictability

BioCryst Pharmaceuticals, Inc. SectorUnited States

Visibility

Analysts' coverage

Financial estimates divergence

Analysts' recommendations divergence

Analysts' Target price divergence

Surprise rates

Rating Revisions

BioCryst Pharmaceuticals, Inc. SectorUnited States

Financial revisions

Revenue revisions (1 year)

Revenue revisions (4 months)

EPS revisions (1 year)

EPS revisions (4 months)

EPS revisions (7 days)

Revenue revisions (7 days)

More ratings

Capi.($) Investor ESG MSCI Fundamentals Financial revisions Global Valuation Visibility Consensus
2.44B -
B
- -
72.12B
AAA
65.85B
A
29.28B - - - -
27.47B -
A
- -
26.7B
AAA
20.06B
A
18.22B
AA
16.4B
AA
-
13.4B
BB
Average 29.19B
AA
Weighted average by Cap.
AA
  1. Stock Market
  2. Stocks
  3. BCRX Stock
  4. Ratings BioCryst Pharmaceuticals, Inc.